Head-To-Head Survey: Adaptimmune Therapeutics (NASDAQ:ADAP) & Atara Biotherapeutics (NASDAQ:ATRA)

Adaptimmune Therapeutics (NASDAQ:ADAP) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

Adaptimmune Therapeutics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Earnings and Valuation

This table compares Adaptimmune Therapeutics and Atara Biotherapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adaptimmune Therapeutics $3.96 million 200.23 -$130.09 million ($0.90) -5.64
Atara Biotherapeutics N/A N/A -$306.62 million ($4.15) -3.91

Adaptimmune Therapeutics has higher revenue and earnings than Atara Biotherapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Adaptimmune Therapeutics and Atara Biotherapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptimmune Therapeutics 1 2 1 0 2.00
Atara Biotherapeutics 0 1 6 0 2.86

Adaptimmune Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 72.24%. Atara Biotherapeutics has a consensus target price of $31.33, suggesting a potential upside of 92.94%. Given Atara Biotherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Adaptimmune Therapeutics.

Institutional and Insider Ownership

71.5% of Adaptimmune Therapeutics shares are held by institutional investors. 15.4% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 3.8% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Adaptimmune Therapeutics and Atara Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adaptimmune Therapeutics -2,391.97% -45.65% -34.39%
Atara Biotherapeutics N/A -82.18% -64.20%

Summary

Adaptimmune Therapeutics beats Atara Biotherapeutics on 7 of the 13 factors compared between the two stocks.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.